Patent · US Active

Methods of producing bioconjugates of E. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof

US11491220B2 · kind B2 · utility

0Cited by

14References

6Claims

0Family size

Assignees

Janssen Pharmaceuticals, Inc. · BE
GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

Jeroen GEURTSEN · Vleuten, NL
Pieter Jan BURGHOUT · Pijnacker, NL
Eveline Marleen Weerdenburg · Uithoorn, NL
Jan Poolman · Broek in Waterland, NL
Kellen Cristhina FAE · Mainz, DE
Patricia IBARRA YON · Solothurn, CH
Darren Robert ABBANAT · Towners, US
Stefan Jochen KEMMLER · Schlieren, CH
Michael Kowarik · Bellinzona, CH
Manuela Mally · Watt, CH
Veronica GAMBILLARA FONCK · Meilen, CH
Martin Edward BRAUN · Friesencham, CH
Maria Paula CARRANZA SANDMEIER · Rudolfstetten, CH

Key dates

Filing date	Mar 18, 2020
Grant date	Nov 8, 2022
Priority date	—
Expiry date	Mar 18, 2040

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.